Comparing the current results to its competitors, Comera Life Sciences Holdings Inc reported Revenue decrease in the 3 quarter 2023 year on year by -41.98 %, despite the revenue increase by the most of its competitors of 11.79 %, recorded in the same quarter.
Comera Life Sciences Holdings Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 88.2 %
Publicly Traded Peers of Comera Life Sciences Holdings Inc
Vistagen Therapeutics Inc Share Performance
-56.89%
This Quarter
Vistagen Therapeutics Inc
Profile
Vistagen Therapeutics Inc is a pharmaceutical company that specializes in developing and commercializing innovative therapies for mental health disorders. Their business model focuses on advanced research and development of novel drug candidates targeting major depressive disorder, social anxiety disorder, and other mental health conditions. By partnering with strategic collaborators and utilizing their proprietary technologies, Vistagen aims to bring effective treatments to patients and address the unmet needs in the mental health sector.
Bristol Myers Squibb Company operates a research and development-driven business model, focusing on the discovery and delivery of innovative medicines for various diseases. It emphasizes collaboration with academic institutions, government entities, and other pharmaceutical firms to enhance its therapeutic portfolio and improve patient outcomes.
Biophytis SA is a biotechnology company that focuses on developing innovative therapeutics for age-related diseases, with a specific emphasis on degenerative eye diseases and muscle wasting conditions. They leverage their expertise in biology and clinical development to discover and advance targeted drug candidates, aiming to address the unmet medical needs of patients in these areas.
Cellectar Biosciences Inc is a biopharmaceutical company that focuses on the development of targeted cancer therapies. They utilize their proprietary drug conjugation platform to create targeted small molecules that can selectively bind and deliver radioactive isotopes directly to cancer cells. Their business model revolves around developing and commercializing these innovative therapies for the treatment of various types of cancer, aiming to improve patient outcomes and potentially revolutionize cancer treatment.
Journey Medical Corporation is a pharmaceutical and medical device company that specializes in developing and commercializing innovative products for dermatology and aesthetics. Their business model revolves around conducting research and development to create new products, acquiring the necessary regulatory approvals, and partnering with healthcare professionals to effectively distribute and market these products. By focusing on dermatology and aesthetics, Journey Medical Corporation aims to address unmet medical needs and provide cutting-edge solutions to improve patient outcomes in these fields.
Sources:
Comera Life Sciences Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Comera Life Sciences Holdings Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
